Securities code: Changchun High And New Technology Industries (Group) Inc(000661) securities abbreviation: Changchun High And New Technology Industries (Group) Inc(000661) Announcement No.: 2022012 Changchun High And New Technology Industries (Group) Inc(000661) technology industry (Group) Co., Ltd
Summary of annual report 2021
1、 Important note: the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC. In addition to the following directors, other directors attended the meeting of the board of directors to consider the annual report in person
Name of director not present in person position of director not present in person reason for not attending the meeting name of the entrusted person
Tips of non-standard audit opinions □ applicable √ not applicable to the profit distribution plan of ordinary shares or the plan of converting provident fund into share capital in the reporting period considered by the board of directors √ applicable □ not applicable whether to convert provident fund into share capital □ yes √ no the company’s profit distribution plan of ordinary shares reviewed and approved by the board of directors is: the current total share capital of 404720290 shares minus the shares held in the special securities account for repurchase shares
Based on 402247089 shares after 2473201 shares, a cash dividend of 8.00 yuan (including tax) will be distributed to all shareholders for every 10 shares, and 0 bonus shares (including tax) will be given. The capital stock will not be converted from the accumulation fund. Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable √ not applicable II. Basic information of the company 1. Company profile
Stock code B
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Zhang Deshen, Liu Si, Li Hongyu, Li Ji
Office address: 27th floor, block B, high tech Hairong Plaza, Changchun City, Jilin Province 27th floor, block B, high tech Hairong Plaza, Changchun City, Jilin Province
Fax 043180557027043180557027
Tel: 043180557027043180557027
E-mail [email protected]. Changchun High And New Technology Industries (Group) Inc(000661) @ccht.jl.cn.
2. Introduction to main business or products during the reporting period
(1) Main business of the company
The company’s main business is the R & D, production and sales of biopharmaceuticals and Chinese patent medicines, supplemented by real estate development, property management and services. After years of industrial layout and R & D investment, the company’s pharmaceutical products cover multiple pharmaceutical segments such as innovative genetic engineering pharmaceuticals, new vaccines and modern traditional Chinese medicine, which are the main source of the company’s performance. The real estate business carries out planned land reserve and is based on the development and operation of characteristic real estate.
The subsidiary kinsay pharmaceutical is mainly engaged in the R & D, production and sales of genetically engineered biological drugs. Its main products are growth hormone series products such as recombinant human growth hormone for injection (powder injection), recombinant human growth hormone injection (water injection), polyethylene glycol recombinant human growth hormone injection (long-acting water injection), assisted reproduction, women’s health, medical devices Children’s nutrition, wound healing and other products.
The subsidiary Changchun Bcht Biotechnology Co(688276) is mainly engaged in the R & D, production and sales of human vaccines. At present, Changchun Bcht Biotechnology Co(688276) and its subsidiary Jilin Huikang Biological Pharmaceutical Co., Ltd. have three approved vaccine products, including live attenuated varicella vaccine, human rabies vaccine (Vero cell) (liquid) Huakang pharmaceutical, a subsidiary of freeze-dried nasal spray live attenuated influenza vaccine (freeze-dried), is mainly engaged in the R & D, production and sales of traditional Chinese medicine, covering cardio cerebrovascular, traditional Chinese medicine anti-inflammatory, women and children and other product lines. Its main products include xueshuxinmaining, Yinhua Biyanling tablets, Shuqing granules, Qingwei Zhitong pellets, etc.
The subsidiary high-tech real estate is mainly engaged in the development and sales of real estate. Based on the development and operation of characteristic real estate for many years, it has successively developed high-tech · Yizhong famous city, high-tech · Heyuan, high-tech · Huiyuan, high-tech · Junyuan, high-tech · Hairong square, high-tech · Rong Park and other projects in Changchun.
(2) Market position of main products
Over the past 20 years since its listing, the company has successfully transformed from its primary business of infrastructure construction of high-tech zone at the beginning of its establishment into an enterprise group focusing on the field of pharmaceutical science and technology innovation and implementing industrial investment. The company insists on seizing the opportunity and focusing on the long-term development goal, continues to promote technology research and development and channel construction, continues to adhere to the investment in the field of pharmaceutical science and technology innovation, implements the industrial strategy of focusing on the pharmaceutical industry and supplemented by the real estate industry, promotes the process of international project cooperation, realizes the scale expansion and benefit leap forward growth, and improves the influence of the company in the China Meheco Group Co.Ltd(600056) field.
As the first recombinant human growth hormone manufacturer in China, kinsay pharmaceutical, a subsidiary, has long been committed to the R & D and production of recombinant human growth hormone, a therapeutic drug for childhood dwarfism. In 1998, kinsay pharmaceutical listed the first domestic recombinant human growth hormone powder injection; In 2005, the first recombinant human growth hormone water injection in Asia was listed; In 2014, the world’s first peg long-acting recombinant human growth hormone water injection was listed. Up to now, kinsay pharmaceutical is the only growth hormone manufacturer in China with a complete product line of powder injection, water injection and long-term water injection. Its long-term water injection is the only long-term growth hormone variety in China, and the product dosage forms and specifications approved in the Chinese market are the most complete. At the same time, the expansion of indications for adult growth hormone deficiency has laid the foundation for the application of the company’s products in relevant adult fields in China. Jinsai pharmaceutical has established a good reputation and brand advantages by virtue of the high-quality quality and curative effect of its products, and continues to maintain its leading position in the field of growth hormone in China.
The subsidiary Changchun Bcht Biotechnology Co(688276) as an innovative biological vaccine enterprise dedicated to the prevention and control of infectious diseases, has been mainly engaged in the R & D, production and sales of human vaccines since its establishment Changchun Bcht Biotechnology Co(688276) at present, it has three approved vaccine products: chickenpox vaccine, rabies vaccine and freeze-dried nasal spray influenza vaccine. During the reporting period, its market share of varicella vaccine has always occupied a leading position. The freeze-dried nasal spray influenza vaccine is the only live attenuated influenza vaccine vaccinated by nasal spray in China.
Changchun Bcht Biotechnology Co(688276) relying on outstanding R & D advantages, mature and perfect industrialization technology, quality management and sales system, we have built a stable profit model.
Huakang Pharmaceutical Co., Ltd., a subsidiary of Huakang Pharmaceutical Co., Ltd., has steadily expanded and strengthened in the past 30 years of operation and development. The representative variety of its cardio cerebrovascular product line, xueshuoxinmaining tablet, has won the first prize for the transformation of scientific and technological achievements in Jilin Province, approved the national traditional Chinese medicine standardization demonstration project, and has become one of the 50 major varieties of traditional Chinese medicine supported and cultivated by the state; Xiaoershuqing oral liquid in the women’s and children’s product line and pseudo ginsenoside GQ injection, a class 1.1 chemical drug under development for the treatment of anti myocardial ischemia, won the “13th five year plan major new drug creation project”, and Yinhua Biyanling tablet in the traditional Chinese medicine anti-inflammatory product line was approved as the “Double Ten Project” project of Jilin Province and the second prize of science and technology of Jilin Province. 3. Main accounting data and financial indicators (1) whether the company needs to retroactively adjust or restate the accounting data of previous years in recent three years □ yes √ no
Unit: Yuan
Year end 2021 year end 2020 year end increase or decrease over the previous year year end 2019 year end
Total assets 22515769520781684462321207 33.67% 1272134798006
Net assets attributable to shareholders of listed companies 14573728469701093100514084 33.32% 808434204299
20212020 year-on-year increase or decrease 2019
Operating income 10746717262218576 Bright Real Estate Group Co.Limited(600708) 50 25.30% 737370126696
Net profit attributable to shareholders of listed company 375747295311304658614521 23.33% 177500919707
Net profit attributable to shareholders of listed companies after deducting non recurring profit and loss of 374209960718295208025335 26.76% 177567606566
Net cash flow from operating activities 333061922529111098985482 199.79% 193467068508
Basic earnings per share (yuan / share) 9.28 7.53 23.24% 10.27
Diluted earnings per share (yuan / share) 9.17 7.46 22.92% 10.27
Weighted average return on net assets 28.81%, 31.22% – 2.41%, 28.54%
(2) Quarterly main accounting data
Unit: Yuan
First quarter second quarter third quarter fourth quarter
Operating income 228130726533268155759659327566037238250819202791
Net profit attributable to shareholders of listed company 8745017262110489815007812237096663461028005978
Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses of 8723957672310494707387512381106074758212249373
Net cash flow from operating activities 615587394336894763120642662241716159893310174
Whether the above financial indicators or their total amount are significantly different from the financial indicators related to the quarterly report and semi annual report disclosed by the company □ yes √ No 4. Share capital and shareholders (1) number of ordinary shareholders and preferred shareholders with voting rights restored and shareholding of the top 10 shareholders
Unit: shares
The disclosure date of the annual report is before the disclosure date of the annual report of voting rights at the end of the reporting period
At the end of the reporting period, the voting rights of preferred shares restored by common 173778 at the end of the month before 137013 were restored
Total number of preferred shareholders with 0 shares
Total number of shareholders
